Hikma Pharmaceuticals (OTCMKTS:HKMPF) Shares Gap Up – What’s Next?

Hikma Pharmaceuticals Plc (OTCMKTS:HKMPF)’s stock price gapped up before the market opened on Thursday . The stock had previously closed at $20.69, but opened at $21.76. Hikma Pharmaceuticals shares last traded at $21.76, with a volume of 750 shares.

Analyst Ratings Changes

Separately, Barclays lowered shares of Hikma Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Tuesday, January 6th. One analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, Hikma Pharmaceuticals has a consensus rating of “Hold”.

Hikma Pharmaceuticals Stock Performance

The company has a fifty day simple moving average of $20.78 and a 200 day simple moving average of $22.41. The company has a current ratio of 1.24, a quick ratio of 0.72 and a debt-to-equity ratio of 0.33.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals is a multinational pharmaceutical company that develops, manufactures and markets a broad range of branded and non-branded generics, specialty injectables and consumer healthcare products. The company’s three core business segments include generic medicines, injectable products and branded generics, serving hospitals, wholesalers and pharmacies worldwide. Its product portfolio spans diverse therapeutic areas such as cardiovascular, oncology, respiratory, pain management and anti-infectives, with an emphasis on injectable solutions for complex hospital treatments.

Founded in 1978 in Amman, Jordan, Hikma has grown through organic expansion and strategic acquisitions to become one of the leading pharmaceutical players in the Middle East, North Africa, Europe and the United States.